LBCA Lobular Breast Cancer Chat: Biomarkers as Tools in ILC

LBCA held a Lobular Breast Cancer Chat: Biomarkers as tools in ILC, LBCA Scientific Advisory Board member Dr. Peter Simpson and his colleague Dr. Amy McCart Reed from the University of Queensland discussed biomarkers and their importance in ILC research. Topics covered include how biomarkers aid in research, the different types and ongoing biomarker discoveries. They also reviewed the context biomarkers are used within ILC research, how they predict treatment benefit and prognosis.

[@RoseGarden86]

Do blood tests ( Invitae & Signatera ) only used in metastatic setting or can it be used for early-stage breast cancer as well to monitor reoccurrence?

[@zaferaksit2009]

IHC (immunohistochemical) biomarkers do not really work, show true prognosis, in ILC or the correct term BCMO (BC of mesenchymal origin). Please look into this issue.